Cover Image
市場調查報告書

美國的抗感染疾病藥物市場 - 2015∼2019年

Infectious Diseases Market in US 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 331968
出版日期 內容資訊 英文 111 Pages
訂單完成後即時交付
價格
Back to Top
美國的抗感染疾病藥物市場 - 2015∼2019年 Infectious Diseases Market in US 2015-2019
出版日期: 2015年06月03日 內容資訊: 英文 111 Pages
簡介

美國的抗感染疾病藥物市場從2014年到2019年的期間預計以3.37%的年複合成長率 (CAGR) 繼續成長。

本報告提供抗感染疾病藥物的美國市場、取得自許多產業專家的資料和資訊,以及推動市場成長要素、市場課題、市場趨勢,還有市場競爭情形的詳細的調查、目前市場方案分析,以及從2015年到2019年的市場成長預測。

第1章 摘要整理

第2章 簡稱表

第3章 本報告涵蓋範圍

  • 市場概要
  • 提供產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 序論

第6章 市場概況

  • 市場概要
  • 市場規模及未來預測
  • 波特的五力分析

第7章 流行病學的分類

  • 病毒感染疾病
  • 真菌感染疾病
  • 細菌感染疾病
  • 寄生蟲性感染疾病

第8章 各藥物類型的市場分類

  • 抗菌藥
    • 美國的抗菌藥市場
  • 抗病毒藥物
    • 美國的抗病毒藥物市場
  • 抗真菌藥物
    • 美國的抗真菌藥物市場
  • 抗寄生蟲藥
    • 美國的抗寄生蟲藥市場

第9章 各藥物給藥途徑的市場分類

  • 口服給藥
  • 非口服給藥
  • 局部給藥

第10章 購買標準

第11章 推動市場成長要素

第12章 推動市場成長要素與其造成的影響

第13章 市場課題

第14章 推動市場成長要素和市場課題帶來的影響

第15章 市場趨勢

第16章 市場趨勢與其造成的影響

第17章 供應商情形

  • 市場競爭方案
    • 重要新聞
    • 企業收購合併
  • 市場佔有率分析
  • 其他關注供應商

第18章 主要供應商分析

  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Pfizer

第19章 相關報告

目錄
Product Code: IRTNTR6000

About Infectious Diseases

Human beings are prone to various kinds of infections. Infectious diseases are caused by various pathogenic microorganisms such as bacteria, fungi, parasites, and viruses. Antimicrobials are used to treat infections. They act by killing or resisting the growth of the microorganisms. They either act via the host defense system or directly target the causative agent. Based on the target organism, antimicrobials can be classified into anti-bacterial, anti-viral, anti-fungal, and anti-parasitic drugs.

Technavio's analysts forecast the infectious diseases market in US to grow at a CAGR of 3.37% over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the infectious diseases market in US for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of drugs administered to treat infectious diseases caused by bacteria, viruses, fungi, and parasites.

The report presents the vendor landscape and a corresponding detailed analysis of the top vendors in the infectious diseases market in US. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

Technavio's report, Infectious Diseases Market in US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. In addition, it discusses the major drivers that influence the growth of the market, challenges faced by the vendors and the market at large, as well as the key trends that contribute to the growth the market.

Key Vendors

  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Pfizer

Other Prominent Vendors

  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb
  • Chimerix Pharmaceuticals
  • Cubist
  • Eli Lilly
  • Isis Pharmaceuticals
  • Mitsubishi Tanabe Pharma
  • Novartis
  • Sanofi
  • Vertex

Market Driver

  • Rise in patient population
  • For a full, detailed list, view our report

Market Challenge

  • Generic erosion
  • For a full, detailed list, view our report

Market Trend

  • Emergence of IFN-free therapies
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
    • 06.2.1. Market Penetration
    • 06.2.2. Marketing Approvals
    • 06.2.3. Patent Protection
    • 06.2.4. Regulatory Designation
    • 06.2.5. Orphan Drug Designation
    • 06.2.6. WHO Recognition
    • 06.2.7. Other Factors
  • 06.3. Five Forces Analysis

07. Epidemiology

  • 07.1. Viral Infections
  • 07.2. Fungal Infections
  • 07.3. Bacterial Infections
  • 07.4. Parasitic Infections

08. Market Segmentation by Type of Drug

  • 08.1. Anti-bacterial Drugs
    • 08.1.1. Anti-bacterial Drugs Market in US
  • 08.2. Anti-viral Drugs
    • 08.2.1. Anti-viral Drugs Market in US
  • 08.3. Anti-fungal Drugs
    • 08.3.1. Anti-fungal Drugs Market in US
  • 08.4. Anti-parasitic Drugs
    • 08.4.1. Anti-parasitic Drugs Market in US

09. Market Segmentation by Route of Administration

  • 09.1. Oral
  • 09.2. Parenteral
  • 09.3. Topical

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

  • 17.1. Competitive Scenario
    • 17.1.1. Key News
    • 17.1.2. Mergers and Acquisitions
  • 17.2. Market Share Analysis 2014
    • 17.2.1. Gilead Sciences
    • 17.2.2. Johnson & Johnson
    • 17.2.3. Merck
    • 17.2.4. Pfizer
    • 17.2.5. F. Hoffmann-La Roche
    • 17.2.6. GlaxoSmithKline
  • 17.3. Other and Future Prominent Vendors

18. Key Vendor Analysis

  • 18.1. F. Hoffmann-La Roche Ltd.
    • 18.1.1. Key Facts
    • 18.1.2. Business Overview
    • 18.1.3. Business Segmentation
    • 18.1.4. Business Segmentation by Revenue 2012 and 2013
    • 18.1.5. Sales by Geography
    • 18.1.6. Business Strategy
    • 18.1.7. Key Information
    • 18.1.8. SWOT Analysis
  • 18.2. Gilead Sciences
    • 18.2.1. Key Facts
    • 18.2.2. Business Overview
    • 18.2.3. Geographical Segmentation by Revenue 2013
    • 18.2.4. Recent Developments
    • 18.2.5. SWOT Analysis
  • 18.3. GlaxoSmithKline
    • 18.3.1. Key Facts
    • 18.3.2. Business Overview
    • 18.3.3. Business Segmentation by Revenue 2014
    • 18.3.4. Business Segmentation by Revenue 2013 and 2014
    • 18.3.5. Geographical Segmentation by Revenue 2014
    • 18.3.6. Business Strategy
    • 18.3.7. Recent Developments
    • 18.3.8. SWOT Analysis
  • 18.4. Johnson & Johnson
    • 18.4.1. Key Facts
    • 18.4.2. Business Overview
    • 18.4.3. Business Segmentation by Revenue 2014
    • 18.4.4. Business Segmentation by Revenue 2013 and 2014
    • 18.4.5. Geographical Segmentation by Revenue 2014
    • 18.4.6. Business Strategy
    • 18.4.7. Recent Developments
    • 18.4.8. SWOT Analysis
  • 18.5. Merck
    • 18.5.1. Key Facts
    • 18.5.2. Business Overview
    • 18.5.3. Business Segmentation by Revenue 2013
    • 18.5.4. Business Segmentation by Revenue 2012 and 2013
    • 18.5.5. Sales by Geography
    • 18.5.6. Business Strategy
    • 18.5.7. Key Developments
    • 18.5.8. SWOT Analysis
  • 18.6. Pfizer
    • 18.6.1. Key Facts
    • 18.6.2. Business Overview
    • 18.6.3. Business Segmentation by Revenue 2014
    • 18.6.4. Business Segmentation by Revenue 2013 and 2014
    • 18.6.5. Geographical Segmentation by Revenue 2014
    • 18.6.6. Business Strategy
    • 18.6.7. Key Developments
    • 18.6.8. SWOT Analysis

19. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Infectious Diseases Market in US 2014-2019 ($ millions)
  • Exhibit 3: Segmentation of Infectious Diseases Market in US by Type of Drug
  • Exhibit 4: Segmentation of Infectious Diseases Market in US by Type of Drug 2014
  • Exhibit 5: Segmentation of Infectious Diseases Market in US by Type of Drug 2019
  • Exhibit 6: Types of Anti-bacterial Drug by Chemical Class
  • Exhibit 7: Anti-bacterial Drugs Market in US 2014-2019 ($ millions)
  • Exhibit 8: Types of Anti-viral Drug by Disease
  • Exhibit 9: Anti-viral Drugs Market in US 2014-2019 ($ millions)
  • Exhibit 10: Types of Anti-fungal Drugs by Chemical Class
  • Exhibit 11: Anti-fungal Drugs Market in US 2014-2019 ($ millions)
  • Exhibit 12: Anti-parasitic Drugs Market in US 2014-2019 ($ millions)
  • Exhibit 13: Segmentation of Infectious Diseases Market in US by Route of Administration
  • Exhibit 14: Segmentation of Infectious Diseases Market in US by Route of Administration 2014
  • Exhibit 15: Gilead Sciences: Revenue of Stribild 2012-2014 ($ millions)
  • Exhibit 16: Gilead Sciences: Revenue of Truvada 2011-2014 ($ millions)
  • Exhibit 17: Gilead Sciences: Revenue of Atripla 2011-2014 ($ millions)
  • Exhibit 18: Gilead Sciences: Revenue of Complera/Eviplera 2011-2014 ($ millions)
  • Exhibit 19: Gilead Sciences: Revenue of Viread 2011-2014 ($ millions)
  • Exhibit 20: Gilead Sciences: Revenue of Hepsera 2011-2013 ($ millions)
  • Exhibit 21: Gilead Sciences: Revenue of AmBisome 2011-2014 ($ millions)
  • Exhibit 22: Gilead Sciences: Percentage Share of Major Anti-infective Drugs 2014
  • Exhibit 23: Johnson & Johnson: YOY Revenue and Growth Rate of Anti-infective Drugs Segment 2011-2014 ($ millions)
  • Exhibit 24: Johnson & Johnson: Revenue of Key Anti-infective Drugs 2011-2014 ($ millions)
  • Exhibit 25: Merck: Key Anti-infective Drugs Portfolio
  • Exhibit 26: Merck: Share of Key Anti-infective Drugs 2014
  • Exhibit 27: Merck: Share of Key Anti-infective Drugs 2011-2014 ($ millions)
  • Exhibit 28: Merck: Sales Comparison of Key Anti-infective Drugs 2011-2014
  • Exhibit 29: Pfizer: Key Anti-infective Drugs Portfolio
  • Exhibit 30: Pfizer: Revenue of Key Anti-infective Drugs 2011-2014
  • Exhibit 31: Pfizer: Share of Key Anti-infective Drugs 2011-2014
  • Exhibit 32: F. Hoffmann-La Roche: Share of Major Anti-infective Drugs 2014
  • Exhibit 33: F. Hoffmann-La Roche: Revenue of Major Anti-infective Drugs 2012-2014 ($ millions)
  • Exhibit 34: GlaxoSmithKline: Key Anti-viral Drugs Portfolio
  • Exhibit 35: GlaxoSmithKline: Revenue of Key Anti-viral Drugs (Except ViiV Healthcare) 2014
  • Exhibit 36: GlaxoSmithKline: Key Anti-bacterial Drugs Portfolio
  • Exhibit 37: GlaxoSmithKline: Share of Augmentin in Anti-bacterial Drugs Segment 2014
  • Exhibit 38: GlaxoSmithKline: Key Anti-HIV Drugs Portfolio (ViiV Healthcare)
  • Exhibit 39: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
  • Exhibit 40: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 41: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 42: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 43: Gilead Sciences: Geographical Segmentation by Revenue 2013
  • Exhibit 44: GlaxoSmithKline: Business Segmentation by Revenue 2014
  • Exhibit 45: GlaxoSmithKline: Business Segmentation by Revenue 2013 and 2014 ($ billion)
  • Exhibit 46: GlaxoSmithKline: Geographical Segmentation by Revenue 2014
  • Exhibit 47: Johnson & Johnson: Business Segmentation by Revenue 2014
  • Exhibit 48: Johnson & Johnson: Business Segmentation by Revenue 2013 and 2014 ($ billion)
  • Exhibit 49: Johnson & Johnson: Geographical Segmentation by Revenue 2014
  • Exhibit 50: Merck: Business Segmentation by Revenue 2013
  • Exhibit 51: Merck: Business Segmentation by Revenue 2012 and 2013 ($ billion)
  • Exhibit 52: Merck: Sales by Geography 2013
  • Exhibit 53: Pfizer: Business Segmentation by Revenue 2014
  • Exhibit 54: Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billion)
  • Exhibit 55: Pfizer: Geographical Segmentation by Revenue 2014
Back to Top